Navigation Links
AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
Date:3/4/2013

o-controlled design, this pivotal Phase 3 study enrolled 178 adult patients at 13 U.S. sites for the treatment of acute post-operative pain immediately following major abdominal surgery.  Patients were treated for post-operative pain for a minimum of 48 hours, and up to 72 hours.  Patients were randomized 2:1, with 119 patients randomized to sufentanil and 59 to placebo treatment.  Both treatments were delivered by the patient, as needed, using the NanoTab System with a 20-minute lock-out period.  Patients in both groups could receive up to 2 mg morphine intravenously per hour as a rescue medication, the primary purpose of this rescue medication being to provide placebo-treated patients access to pain medication to enable them to stay in the study as long as possible.  Pre-rescue pain scores were imputed to minimize the impact of this rescue opioid on efficacy evaluations.

Eighty, or 70.2% of the sufentanil NanoTab-treated patients completed the 48-hour study period, compared to 30 (51.7%) placebo-treated patients.  Reasons for drop-out in the sufentanil- and placebo-treated groups were adverse events (5.3% and 6.9% respectively), lack of efficacy (16.7% and 31.0% respectively) and other (7.9% and 10.3% respectively).  The primary endpoint measure, SPID-48, was 105.6 for sufentanil-treated patients and 55.6 for placebo-treated patients (p=0.001). 

Treatment-emergent adverse events occurred in 64.0% of sufentanil-treated patients and 67.2% of placebo-treated patients.  Adverse events with an occurrence greater than 5% in either the sufentanil group or the placebo group were nausea (30.7% and 41.4% respectively), fever (14.9% and 8.6% respectively), vomiting (8.8% and 6.9% respectively), itching (8.8% and 0.0% respectively), oxygen saturation decrease (6.1% and 1.7% respectively), and hypertension (2.6% and 5.2% respectively).  Itching, a frequently observed side effect of opioids, was the only adverse e
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. AcelRx Pharmaceuticals Provides Clinical Trial Updates
3. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
4. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
6. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
10. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
11. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... April 13, 2011 Cephalon, Inc. (Nasdaq: ... CXS Holdings Pty Ltd (Cephalon), has lodged the offer ... for ChemGenex Pharmaceuticals Limited (ASX: CXS) (ChemGenex) with the ... offering a 58 percent premium to the one-month volume ...
... Pharmaceuticals, Inc., the leader in the development of neurosteroids ... of a $3 million grant by the U.S. Department ... the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ... Early research suggests that normalizing neurosteroid levels with ganaxolone ...
Cached Medicine Technology:Cephalon Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals 2Cephalon Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals 3Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome 2
(Date:4/23/2014)... State University Spokane have developed a new way ... off behind the wheel. , Their recently patented ... more variable in drowsy driversand offers an affordable ... driver drowsiness detection systems. , Van Dongen"Video-based systems ... is drifting out of its lane are cumbersome ...
(Date:4/23/2014)... University researcher is looking to give exercise enthusiasts the ... latest research shows that a cyber buddy can help. ... for Health Journal , is the first to indicate ... motivator during exercise, a software-generated partner also can be ... isn,t real can still motivate people to give greater ...
(Date:4/23/2014)... rats exposed to high-energy particles, simulating conditions astronauts would ... in attention and slower reaction times, even when the ... The cognitive impairments which affected a large subset, ... to be linked to protein changes in the brain, ... true in humans, suggest it may be possible to ...
(Date:4/23/2014)... researchers have identified an important enzyme pathway that helps ... few chromosomes, a condition that has been directly linked ... professor of biochemistry, found that near the end of ... that ensures any breaks in DNA are fully repaired ... to daughter cells. This process helps safeguard against some ...
(Date:4/23/2014)... has long been considered to be between 180 and ... used refined microscopic techniques that indicate a much smaller ... tract is only as large as a normal studio ... which passes from the mouth through the esophagus and ... 5 meters in a normal adult, and is built ...
Breaking Medicine News(10 mins):Health News:WSU innovation improves drowsy driver detection 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... THE MARKET FORECAST FOR THE DRUG, WALTHAM, Mass., ... Resources, is available to discuss the impact of the ... the,first integrase inhibitor drug which blocks the ability of ... Integrase inhibitors are a novel class of HIV drugs ...
... New products, a growing world,population expected to ... as the,aging of that population, will push anesthesia ... according to Anesthesia Drugs: Worldwide Markets, a,new report ... surgical procedures required anesthetic,administration worldwide in 2006, and ...
... SYK ) disclosed today that the United ... inquiry of the Company regarding possible,violations of the ... sale,of medical devices in certain foreign countries. Stryker ... Commission regarding this,informal investigation. Stryker Corporation is ...
... 118 patients with portal vein thrombosis, noncirrhotic and nontumoral ... well tolerated bleed. Cirrhosis and tumor related portal vein ... state as a cause of portal vein thrombosis is ... number of patients. , A research article to be ...
... health information program recognized for helping to reduce, ... self-care., INDIANAPOLIS, Oct. 12 WellPoint NextRx, ... has received a 2007,Disease Management Leadership Award from ... innovative, Web-based Health Envelope(R) Program.,WellPoint NextRx is owned ...
... /Xinhua-PRNewswire-FirstCall/ -- China,Medicine Corporation ("CMC") (OTC ... prescription and over the counter pharmaceutical ... of Chinese herbs),Chinese herbs, nutritional supplements, ... today announced the Company,s ADTZ,(Aflatoxin-detoxifizyme) project ...
Cached Medicine News:Health News:Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients 2Health News:Anesthesia Drugs Market to Grow to $4.3 Billion by 2011 as Populations and Uses for Anesthesia Increase 2Health News:Portal vein thrombosis is common in extraportal vein obstruction 2Health News:WellPoint NextRx Receives National Leadership Award for Innovative Web Tool 2Health News:WellPoint NextRx Receives National Leadership Award for Innovative Web Tool 3Health News:China Medicine's ADTZ Project Has Been Selected as One of Six Patent Commercialization Projects in Guangdong Province 2
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Gradua...
Laser resistant tubes for use with CO2 and KTP Lasers., ,Designed for airway management during laser surgery of the larynx or other areas in close proximity to the trachea....
Laryngectomy Tubes with special J-shape for convenient placement through a tracheostomy stoma....
SPIRAL-FLEX® Reinforced Oral/Nasal Cuffed Endotracheal Tubes...
Medicine Products: